D-0282-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0282-2021 was initiated by Teva Pharmaceuticals USA on Feb 10, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable… The recall status is terminated (terminated May 15, 2024).

Recall details

Product Type
Drugs
Report Date
Mar 3, 2021
Initiation Date
Feb 10, 2021
Termination Date
May 15, 2024
Voluntary/Mandated
Voluntary: Firm initiated

Product description

MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0045-01.

Reason for recall

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Distribution pattern

Product was distributed nationwide in the USA and Puerto Rico.

Code information

Lot # 31327725B, exp. date 02/2021 Lot # 31327906B, exp. date 03/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0282-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0282-2021. Report a data issue: hello@regdatalab.com.